Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Refractory/Relapsed AIHA
NCT06847607Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iptacopan in autoimmune hemolytic anemia (AIHA). Primary endpoints: Overall Response at 3 months and Complete Response at 6 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
Iptacopan
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT06847607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847607.